利伐沙班与华法林治疗静脉血栓栓塞症比较研究.docVIP

利伐沙班与华法林治疗静脉血栓栓塞症比较研究 　　[摘要] 目的 探讨利伐沙班与华法林治疗静脉血栓栓塞症的效果。方法 随机选取2015年6月―2017年6月在该院治疗的90例静脉血栓栓塞症的患者作为研究对象，研究周期为一例患者随访半年的方法，将其分为对照组和观察组各45例。对照组给予华法林治疗，观察组给予利伐沙班治疗。比较两组的治疗效果。结果 观察组血栓栓塞症状缓解时间（17.2±1.9）d，对照组的为（17.5±1.9）d，两者差异无统计学意义（P0.05）。观察组的血栓复发率为4.44%，对照组的血栓复发率为6.66%（P0.05）。观察组患者D-2聚体下降时间为（7.0±2.1）d明显低于对照组的（9.0±3.0）d，观察组患者的出血发生率为4.44%明显低于对照组的17.78%（P0.05）。结论 利伐沙班用于静脉血栓栓塞症的治疗，疗效显著，出血发生率低，无需监测INR值，无需调整药物剂量，十分安全方便，值得在临床上进一步探讨和推广。 　　[关键词] 利伐沙班；华法林；静脉血栓栓塞症 　　[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2017）12（b）-0120-03 　　[Abstract] Objective To study the effect of rivaroxaban and warfarin in treatment of venous thromboembolism. Methods 90 cases of patients with venous thromboembolism treated in our hospital from June 2015 to June 2017 were selected as the research objects， and each case was followed up for half a year， and the patients were divided into two groups with 45 cases in each， the control group and the observation group were treated with warfarin and rivaroxaban， and the treatment effect was compared between the two groups. Results The relief time of thrombo-embolism in the observation group and in the control group was respectively （17.2±1.9）d and （17.5±1.9）d， and the difference was not statistically significant（P0.05）， and the thrombus recurrent rate in the observation group and in the control group was respectively 4.44% and 6.66%（P0.05）， and the D-2 polymer decrease time in the observation group was obviously lower than that in the control group， [（7.0±2.1）d vs （9.0±3.0）d]， and the incidence rate of hemorrhage in the observation group was obviously lower than that in the control group， （4.44% vs 17.78%）（P0.05）. Conclusion The curative effect of rivaroxaban in treatment of venous thromboembolism is obvious， and the incidence rate of hemorrhage is low， and it is very safe and convenient without monitoring INR value and adjusting the drug dose， and it is worth clinical promotion and application. 　　[Key words] Rivaroxaban； Warfarin； Venous thromboembolism 　　?o脉血栓